Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217984 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Akash Sabarwal und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Receptor Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-met, Oxidative Stress. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, US Department of Defense.
Abstract (Originalsprache)
The mechanisms underlying therapeutic resistance to c-Met/receptor tyrosine kinase (RTK) inhibitors in renal cancer remain unexplored. In renal cell carcinoma (RCC) cells, both AXL and c-Met are highly upregulated. Notably, we found that prolonged treatment with the c-Met/RTK inhibitor, cabozantinib (Cabo), a standard treatment for advanced-stage RCC, markedly increased total c-Met levels and promoted renal cancer cell proliferation. This effect was confirmed not only in vitro but also in murine models and renal tumor tissues from Cabo-treated patients. At lower concentrations (1 nM and 10 nM), Cabo treatment failed to inhibit HGF (c-Met ligand)-induced c-Met phosphorylation. Instead, it further enhanced receptor phosphorylation and downstream signaling events for tumor growth. Additionally, Cabo treatment induced AXL-c-Met association and disrupted the physiological degradation of c-Met. However, inhibition or knockout of AXL could significantly overcome therapeutic resistance to c-Met inhibitor(s). It triggered apoptotic cell death through increased oxidative stress and inhibition of the redox-sensitive transcription factor, Nrf2 and its effector molecule, heme oxygenase-1 (HO-1). We also generated Cabo-resistant RCC cells and observed a marked upregulation of both c-Met and AXL in these cells. Epigenomic profiling revealed significant differences between Cabo-resistant and Cabo-sensitive RCC cells. Importantly, inhibition of AXL either using a potent inhibitor, TP-0903, or through genetic silencing resensitized the resistant cells to Cabo-induced cell death. Together, our findings highlight AXL as a key driver of therapeutic resistance to c-Met inhibitors. A combination therapy targeting both c-Met and AXL in renal cancer could be a promising strategy to overcome the acquired resistance to c-Met inhibitors through increased oxidative stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Division of Nephrology, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Transplant Research Program, Boston Children's Hospital, Boston, MA, USA; Computational Health Informatics Pr…
- Harvard Medical School, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Center for Immuno-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Division of Nephrology, Boston Children's Hospital, Boston, MA, USA; Division of Genetics, Brigham and Women's Hospital, Boston, MA, USA; Department of Ophthalmology, Boston University Chobanian & Avedisian School of Me…
- Division of Nephrology, Boston Children's Hospital, Boston, MA, USA; University Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Förderung
- NCI NIH HHS
- National Institutes of Health
- US Department of Defense
- Deutsche Forschungsgemeinschaft
- Dana-Farber Cancer Institute
- Dana Foundation
- Harvard Medical School
- American Society of Nephrology
Zitieren
APA
Sabarwal, A., Machaalani, M., Rawat, L., Wedel, J., Tabasum, S., Sasamoto, Y., Buerger, F., Ascione, J., Eid, M., Semaan, K., Saad, E., Yang, Y., Lee, D., Hodi, F. S., Freedman, M. L., Mary Lee, G. S., Balan, M., Choueiri, T. K., & Pal, S. (2025). Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217984
Vancouver
Sabarwal A, Machaalani M, Rawat L, Wedel J, Tabasum S, Sasamoto Y, et al. Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217984
BibTeX
@article{Sabarwal2025,
author = {Sabarwal, Akash and Machaalani, Marc and Rawat, Laxminarayan and Wedel, Johannes and Tabasum, Saba and Sasamoto, Yuzuru and Buerger, Florian and Ascione, Josie and Eid, Marc and Semaan, Karl and Saad, Eddy and Yang, Yifan and Lee, Dongwon and Hodi, F Stephen and Freedman, Matthew L and Mary Lee, Gwo-Shu and Balan, Murugabaskar and Choueiri, Toni K and Pal, Soumitro},
title = {Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217984}
}
EUVIMED